Jefferies analyst Roger Song maintained a Buy rating on Tourmaline Bio (TRML – Research Report) yesterday and set a price target of $64.00.Stay ...

Tourmaline Bio has released an updated corporate presentation detailing its progress and future plans, including significant clinical trial milestones for its lead product, pacibekitug.

BitMEX co-founder Arthur Hayes has conveyed a highly bullish outlook for the DeSci crypto project Bio Protocol (BIO) amid major listings.

Let’s take a look at Bio-Rad Laboratories’s outlook and value based on the most recent financial ... Are you a shareholder? BIO’s optimistic future growth appears to have been factored into the ...